(Total Views: 360)
Posted On: 07/07/2021 4:38:59 PM
Post# of 30067
Todos mentioned in the article bellow about drugs for Alzheimer's
https://seekingalpha.com/article/4438096-biog...e-insights
Todos Medical (OTCQB:TOMDF), a company with a serum Alzheimer’s diagnostic in development that very closely aligns with the gold standard of Alzheimer’s diagnosis, amyloid PET cSUVR, views Alzheimer’s as “cancer of neuronal cells that are incapable of completing cell division due to their post-mitotic nature,” where neurons are trying to, but mostly cannot undergo mitosis (cell division), and that this dysfunction is mirrored in peripheral lymphocytes. What is interesting is, despite the diagnostic’s excellent correlation with amyloid PET (r = -0.848), their view of the disease is not at all an amyloid beta-driven theory. This is certainly an interesting view, and could be part of the Alzheimer’s puzzle. Personally, I believe there is quite a strong case to be made for neuroinflammation, at least as part of the problem and a good target for solution, even if it's not a primary driver. Todos’ LymPro test is immune-cell based, measuring CD69 in peripheral blood lymphocytes as a marker of entering the cell cycle. An algorithm ties this to a score, diagnosing MCI, and this will provide an extra step before going to get a scan.
https://seekingalpha.com/article/4438096-biog...e-insights
Todos Medical (OTCQB:TOMDF), a company with a serum Alzheimer’s diagnostic in development that very closely aligns with the gold standard of Alzheimer’s diagnosis, amyloid PET cSUVR, views Alzheimer’s as “cancer of neuronal cells that are incapable of completing cell division due to their post-mitotic nature,” where neurons are trying to, but mostly cannot undergo mitosis (cell division), and that this dysfunction is mirrored in peripheral lymphocytes. What is interesting is, despite the diagnostic’s excellent correlation with amyloid PET (r = -0.848), their view of the disease is not at all an amyloid beta-driven theory. This is certainly an interesting view, and could be part of the Alzheimer’s puzzle. Personally, I believe there is quite a strong case to be made for neuroinflammation, at least as part of the problem and a good target for solution, even if it's not a primary driver. Todos’ LymPro test is immune-cell based, measuring CD69 in peripheral blood lymphocytes as a marker of entering the cell cycle. An algorithm ties this to a score, diagnosing MCI, and this will provide an extra step before going to get a scan.
(2)
(0)
